8BZY

Structure of SLC40/ferroportin in complex with vamifeport and synthetic nanobody Sy3 in occluded conformation

8BZY の概要

• エントリーDOI: 10.2210/pdb8bzy/pdb
• EMDBエントリー: 16345
• 分子名称: Solute carrier family 40 member 1, Sybody 3, DIUNDECYL PHOSPHATIDYL CHOLINE, ... (4 entities in total)
• 機能のキーワード: iron, inhibitor, slc40, transporter, transport protein
• 由来する生物種: Homo sapiens (human); 詳細
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 80911.21

構造登録者

Lehmann, E.F.,Liziczai, M.,Drozdzyk, K.,Dutzler, R.,Manatschal, C. (登録日: 2022-12-15, 公開日: 2023-03-22, 最終更新日: 2025-07-02)

主引用文献

Lehmann, E.F.,Liziczai, M.,Drozdzyk, K.,Altermatt, P.,Langini, C.,Manolova, V.,Sundstrom, H.,Durrenberger, F.,Dutzler, R.,Manatschal, C.
Structures of ferroportin in complex with its specific inhibitor vamifeport.
Elife, 12:-, 2023

PubMed Abstract: A central regulatory mechanism of iron homeostasis in humans involves ferroportin (FPN), the sole cellular iron exporter, and the peptide hormone hepcidin, which inhibits Fe transport and induces internalization and degradation of FPN. Dysregulation of the FPN/hepcidin axis leads to diverse pathological conditions, and consequently, pharmacological compounds that inhibit FPN-mediated iron transport are of high clinical interest. Here, we describe the cryo-electron microscopy structures of human FPN in complex with synthetic nanobodies and vamifeport (VIT-2763), the first clinical-stage oral FPN inhibitor. Vamifeport competes with hepcidin for FPN binding and is currently in clinical development for β-thalassemia and sickle cell disease. The structures display two distinct conformations of FPN, representing outward-facing and occluded states of the transporter. The vamifeport site is located in the center of the protein, where the overlap with hepcidin interactions underlies the competitive relationship between the two molecules. The introduction of point mutations in the binding pocket of vamifeport reduces its affinity to FPN, emphasizing the relevance of the structural data. Together, our study reveals conformational rearrangements of FPN that are of potential relevance for transport, and it provides initial insight into the pharmacological targeting of this unique iron efflux transporter.

PubMed: 36943194
DOI: 10.7554/eLife.83053

実験手法

ELECTRON MICROSCOPY (3.24 Å)